ABBV-319 elicits antitumor effects through 3 distinct MOA. ABBV-319 results in CD19 internalization and lysosomal trafficking to release GRM payload. GRM payload drives the transcriptional activation of GR targets (eg, BCL2L11) to activate apoptotic cell death. ABBV-319 also blocks CD19-mediated activation of the PI3K pathway. Lastly, afucosylation of the Fc region enhances ADCC driven by effector cells.